Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

Simoctocog alfa (human-cl rhFVIII, Nuwiq®) is a 4th generation recombinant FVIII (rFVIII), without chemical modification or fusion with any other protein/fragment. Nuwiq® is produced in a human embryonic kidney cell line (HEK293F), which ensures human-specific post-translational protein processing....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ther Adv Hematol
Glavni autori: Lissitchkov, Toshko, Klukowska, Anna, Pasi, John, Kessler, Craig M., Klamroth, Robert, Liesner, Raina J., Belyanskaya, Larisa, Walter, Olaf, Knaub, Sigurd, Bichler, Johann, Jansen, Martina, Oldenburg, Johannes
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2019
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595650/
https://ncbi.nlm.nih.gov/pubmed/31263528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719858471
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items